Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication

An active substance, nicotine technology, applied in the direction of drug combination, organic active ingredients, drug delivery, etc., can solve the problem that caffeine cannot be used to overcome psychological dependence and increase the risk of smoking cessation again.

Inactive Publication Date: 2003-06-11
LTS LOHMANN THERAPIE-SYST AG
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, caffeine cannot be used to overcome psychological dependence
In addition, side effects caused by caffeine, such as irritability, nervousness, or muscle tremors, increase the risk of relapse in ex-smokers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] In one group of embodiments of the present invention, the transdermal dosage form is in the form of a transdermal therapeutic system (TTS), which can be adhered to the patient's skin as a patch of active substances, where they are then passed through the skin. Release the active substance. The structure of such a system basically comprises an active substance-impermeable backing layer, an active substance reservoir bonded to the aforementioned backing layer, preferably pressure sensitive adhesive, and a protective layer which can be removed prior to application . The active substance reservoir comprises a combination of at least two active substances, namely nicotine, nicotine salts, nicotine derivatives or nicotine-like substances, and at least one central nervous system-acting substance or group of substances substances as additional active ingredients.

[0019] In transdermal therapeutic systems (TTS), the active substance reservoir of the TTS containing the active...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A transdermal or transmucosal pharmaceutical administration form for treating nicotine dependency or for disaccustoming smokers, comprising nicotine, a nicotine salt, a nicotine derivative or a nicotinergic substance in combination with at least one further active substance is characterized in that as additional active substance(s) it comprises at least one substance which acts on the central nervous system.

Description

field of invention [0001] The present invention relates to transdermal or transmucosal pharmaceutical dosage forms for the treatment of nicotine dependence or cravings in ex-smokers, comprising nicotine, nicotine salts, nicotine derivatives or nicotine in combination with additional active substances class of substances. [0002] The present invention also relates to the use of such dosage form for the treatment of nicotine dependence, as a nicotine substitute, or for quitting smoking, and also to the use of nicotine and / or its salts or derivatives for the manufacture of nicotine dependence Use of transdermal or transmucosal pharmaceutical forms. Background of the invention [0003] Although it is common knowledge that smoking is harmful to health, it is very difficult for most of those who are dependent on nicotine to end this dependence. The main reason is the nicotine withdrawal symptoms after tobacco smoking is exhausted. If the need for nicotine is met, in other word...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K9/70A61K31/465A61K45/00A61K45/06A61K47/32A61K47/36A61K47/38A61P25/00A61P25/02A61P25/18A61P25/24A61P25/26A61P25/34
CPCA61K9/006A61K9/7023A61K45/06A61K31/465A61P25/00A61P25/02A61P25/18A61P25/20A61P25/22A61P25/24A61P25/26A61P25/28A61P25/30A61P25/34A61K31/00A61K2300/00
Inventor 法兰克·堤尔拔乌尔丽希·弗瑞克
Owner LTS LOHMANN THERAPIE-SYST AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com